DCLK1 and cancer: In our long term in vivo efficacy study, we demonstrated that licofelone can target arachidonic acid metabolites derived from COX-2 and 5-LOX, cancer stem cell markers (DclK1, CD133, CD44 and Lgr5) and specific miRNAs and their target genes and can potently inhibit PanIN progression to PDAC without any unwanted side-effects.